Table 1.
Available patients’ data
| Pathology | Gender | AED | Experimental use | |
|---|---|---|---|---|
| 1 | TLE | F | LCM; PGB | IHC |
| 2 | TLE | M | TPM, PBT | IHC |
| 3 | TLE | F | LMT; LEV; PRM; OXC | IHC |
| 4 | TLE | F | NA | IHC, WB |
| 5 | TLE | F | CBZ, VPA, GBP, LMT, PHT, PBT, TPM, OXC, LEV | IHC, WB |
| 6 | TLE | F | NA | IHC, WB |
| 7 | TLE | F | LEV; OXC; LMT | HPLC, WB |
| 8 | TLE | F | LMT; GBP; PGB; LEV | HPLC |
| 9 | TLE | F | LMT | HPLC |
AEDs, antiepileptic drugs; TPM, topiramate; PHT, phenytoin; PBT, phenobarbital; PRM, primidone; PGB, pregabalin; GBP, gabapentin; DZ, diazepam; CBZ, carbamazepine; VPA, valproic acid; LEV, levetiracetam; LCM, lacosamide; LMT, lamotrigine; OXC, oxcarbamazepine; TLE, temporal lobe epilepsy; IHC, immunohistochemistry; WB, western blotting; HPLC, high performance liquid chromatography; NA, not available.